probucol降低II型高脂蛋白血症患者血浆大、轻LDL (LDL1)、HDL2和HDL3水平，同时升高胆固醇酯转移蛋白(CETP)活性

Artery Pub Date : 1993-01-01

Y Homma, T Kobayashi, H Yamaguchi, H Sakane, H Ozawa, M Matsuda, Y Mikami, Y Mikami, H Nakamura

{"title":"probucol降低II型高脂蛋白血症患者血浆大、轻LDL (LDL1)、HDL2和HDL3水平，同时升高胆固醇酯转移蛋白(CETP)活性","authors":"Y Homma, T Kobayashi, H Yamaguchi, H Sakane, H Ozawa, M Matsuda, Y Mikami, Y Mikami, H Nakamura","doi":"","DOIUrl":null,"url":null,"abstract":"The effects of 12 week probucol treatment on plasma lipoprotein subfraction levels and on lecithin: cholesterol acyltransferase (LCAT) and cholesteryl ester transfer protein (CETP) activities in type II hyperlipoproteinemia were investigated. Plasma VLDL-TG, VLDL-apoB, VLDL-apoCII and VLDL-apoCIII concentrations were not changed by probucol, but VLDL-TC and VLDL-PL levels were slightly reduced. Probucol slightly reduced plasma IDL-TC, but not IDL-TG, IDL-PL and IDL-apoB levels. Plasma large, light LDL (LDL1)-TC, LDL1-PL, LDL1-apoB levels were decreased significantly by 28.5 +/- 20.1% (p < 0.001), 18.1 +/- 18.8% (p < 0.01) and 23.3 +/- 19.1% (p < 0.001) by probucol treatment while LDL1-TG concentration was unchanged. Absolute amounts of plasma small, heavy LDL(LDL2)-TC, LDL2-TG, LDL2-PL and LDL2-apoB levels remained unchanged but percent increases of LDL2-TC and LDL2-apoB were statistically significant (p < 0.05). 2-16% gradient polyacrylamide gel electrophoresis demonstrated the diminution of LDL of large size by probucol treatment. Probucol markedly reduced plasma high density lipoprotein levels. The reductions of HDL2-TC, HDL2-TG, HDL2-PL and HDL2-apoAI concentrations were 36.2 +/- 25.4% (p < 0.001), 25.8 +/- 36.9% (p < 0.01), 34.4 +/- 23.8% (p < 0.001) and 35.6 +/- 28.4% (p < 0.001). Probucol significantly decreased plasma HDL3-TC, HDL3-PL and HDL3-apoAI amounts by 17.4 +/- 22.9% (p < 0.01), 18.3 +/- 20.8% (p < 0.01) and 19.8 +/- 27.9% (p < 0.01) without change of HDL3-TG level. The decrease of HDL2 level was more marked than that of HDL3 level. Probucol did not change LCAT activities. Probucol significantly stimulated CETP activities from 126.6 +/- 50.6 units to 172.8 +/- 40.2 units by 12 week treatment (p < 0.001). We concluded that probucol decreased plasma LDL1, HDL2 and HDL3 amounts and made them triglyceride-rich with the concomitant increase of CETP activities.","PeriodicalId":75564,"journal":{"name":"Artery","volume":"20 1","pages":"1-18"},"PeriodicalIF":0.0000,"publicationDate":"1993-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Decrease of plasma large, light LDL (LDL1), HDL2 and HDL3 levels with concomitant increase of cholesteryl ester transfer protein (CETP) activity by probucol in type II hyperlipoproteinemia.\",\"authors\":\"Y Homma, T Kobayashi, H Yamaguchi, H Sakane, H Ozawa, M Matsuda, Y Mikami, Y Mikami, H Nakamura\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The effects of 12 week probucol treatment on plasma lipoprotein subfraction levels and on lecithin: cholesterol acyltransferase (LCAT) and cholesteryl ester transfer protein (CETP) activities in type II hyperlipoproteinemia were investigated. Plasma VLDL-TG, VLDL-apoB, VLDL-apoCII and VLDL-apoCIII concentrations were not changed by probucol, but VLDL-TC and VLDL-PL levels were slightly reduced. Probucol slightly reduced plasma IDL-TC, but not IDL-TG, IDL-PL and IDL-apoB levels. Plasma large, light LDL (LDL1)-TC, LDL1-PL, LDL1-apoB levels were decreased significantly by 28.5 +/- 20.1% (p < 0.001), 18.1 +/- 18.8% (p < 0.01) and 23.3 +/- 19.1% (p < 0.001) by probucol treatment while LDL1-TG concentration was unchanged. Absolute amounts of plasma small, heavy LDL(LDL2)-TC, LDL2-TG, LDL2-PL and LDL2-apoB levels remained unchanged but percent increases of LDL2-TC and LDL2-apoB were statistically significant (p < 0.05). 2-16% gradient polyacrylamide gel electrophoresis demonstrated the diminution of LDL of large size by probucol treatment. Probucol markedly reduced plasma high density lipoprotein levels. The reductions of HDL2-TC, HDL2-TG, HDL2-PL and HDL2-apoAI concentrations were 36.2 +/- 25.4% (p < 0.001), 25.8 +/- 36.9% (p < 0.01), 34.4 +/- 23.8% (p < 0.001) and 35.6 +/- 28.4% (p < 0.001). Probucol significantly decreased plasma HDL3-TC, HDL3-PL and HDL3-apoAI amounts by 17.4 +/- 22.9% (p < 0.01), 18.3 +/- 20.8% (p < 0.01) and 19.8 +/- 27.9% (p < 0.01) without change of HDL3-TG level. The decrease of HDL2 level was more marked than that of HDL3 level. Probucol did not change LCAT activities. Probucol significantly stimulated CETP activities from 126.6 +/- 50.6 units to 172.8 +/- 40.2 units by 12 week treatment (p < 0.001). We concluded that probucol decreased plasma LDL1, HDL2 and HDL3 amounts and made them triglyceride-rich with the concomitant increase of CETP activities.\",\"PeriodicalId\":75564,\"journal\":{\"name\":\"Artery\",\"volume\":\"20 1\",\"pages\":\"1-18\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1993-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Artery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Artery","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

研究了普罗布考治疗12周后对II型高脂蛋白血症患者血浆脂蛋白亚段水平及卵磷脂:胆固醇酰基转移酶(LCAT)和胆固醇酯转移蛋白(CETP)活性的影响。丙布考对血浆VLDL-TG、VLDL-apoB、VLDL-apoCII和VLDL-apoCIII浓度无显著影响，但VLDL-TC和VLDL-PL水平略有降低。普罗布考可轻微降低血浆IDL-TC水平，但不能降低IDL-TG、IDL-PL和IDL-apoB水平。probucol组血浆大、轻LDL (LDL1)- tc、LDL1- pl、LDL1- apob水平分别显著降低28.5 +/- 20.1% (p < 0.001)、18.1 +/- 18.8% (p < 0.01)和23.3 +/- 19.1% (p < 0.001)，而LDL1- tg水平不变。血浆小、重LDL(LDL2)-TC、LDL2- tg、LDL2- pl和LDL2- apob的绝对水平保持不变，但LDL2-TC和LDL2- apob的百分比升高有统计学意义(p < 0.05)。2-16%梯度聚丙烯酰胺凝胶电泳显示普罗布考对大尺寸LDL有降低作用。普罗布考显著降低血浆高密度脂蛋白水平。HDL2-TC、HDL2-TG、HDL2-PL和HDL2-apoAI浓度分别降低36.2 +/- 25.4% (p < 0.001)、25.8 +/- 36.9% (p < 0.01)、34.4 +/- 23.8% (p < 0.001)和35.6 +/- 28.4% (p < 0.001)。Probucol显著降低血浆HDL3-TC、HDL3-PL和HDL3-apoAI水平，分别为17.4 +/- 22.9% (p < 0.01)、18.3 +/- 20.8% (p < 0.01)和19.8 +/- 27.9% (p < 0.01)，但HDL3-TG水平不变。HDL2水平的下降比HDL3水平的下降更明显。普罗布考没有改变LCAT活性。经12周治疗，普罗布考显著刺激CETP活性，从126.6 +/- 50.6个单位增加到172.8 +/- 40.2个单位(p < 0.001)。我们得出结论，普罗布科尔降低血浆LDL1、HDL2和HDL3的含量，使它们富含甘油三酯，同时增加CETP活性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

本刊更多论文

Decrease of plasma large, light LDL (LDL1), HDL2 and HDL3 levels with concomitant increase of cholesteryl ester transfer protein (CETP) activity by probucol in type II hyperlipoproteinemia.

The effects of 12 week probucol treatment on plasma lipoprotein subfraction levels and on lecithin: cholesterol acyltransferase (LCAT) and cholesteryl ester transfer protein (CETP) activities in type II hyperlipoproteinemia were investigated. Plasma VLDL-TG, VLDL-apoB, VLDL-apoCII and VLDL-apoCIII concentrations were not changed by probucol, but VLDL-TC and VLDL-PL levels were slightly reduced. Probucol slightly reduced plasma IDL-TC, but not IDL-TG, IDL-PL and IDL-apoB levels. Plasma large, light LDL (LDL1)-TC, LDL1-PL, LDL1-apoB levels were decreased significantly by 28.5 +/- 20.1% (p < 0.001), 18.1 +/- 18.8% (p < 0.01) and 23.3 +/- 19.1% (p < 0.001) by probucol treatment while LDL1-TG concentration was unchanged. Absolute amounts of plasma small, heavy LDL(LDL2)-TC, LDL2-TG, LDL2-PL and LDL2-apoB levels remained unchanged but percent increases of LDL2-TC and LDL2-apoB were statistically significant (p < 0.05). 2-16% gradient polyacrylamide gel electrophoresis demonstrated the diminution of LDL of large size by probucol treatment. Probucol markedly reduced plasma high density lipoprotein levels. The reductions of HDL2-TC, HDL2-TG, HDL2-PL and HDL2-apoAI concentrations were 36.2 +/- 25.4% (p < 0.001), 25.8 +/- 36.9% (p < 0.01), 34.4 +/- 23.8% (p < 0.001) and 35.6 +/- 28.4% (p < 0.001). Probucol significantly decreased plasma HDL3-TC, HDL3-PL and HDL3-apoAI amounts by 17.4 +/- 22.9% (p < 0.01), 18.3 +/- 20.8% (p < 0.01) and 19.8 +/- 27.9% (p < 0.01) without change of HDL3-TG level. The decrease of HDL2 level was more marked than that of HDL3 level. Probucol did not change LCAT activities. Probucol significantly stimulated CETP activities from 126.6 +/- 50.6 units to 172.8 +/- 40.2 units by 12 week treatment (p < 0.001). We concluded that probucol decreased plasma LDL1, HDL2 and HDL3 amounts and made them triglyceride-rich with the concomitant increase of CETP activities.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Artery

自引率

0.00%

发文量